Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the hypothesis that quetiapine XR (Extended Release)
monotherapy or adjunctive therapy to antidepressant is superior to placebo monotherapy or
placebo adjunctive therapy to antidepressant(s) in the acute treatment of depression symptoms
in patients with MDD and comorbid GAD. The secondary objectives are to test the hypotheses
that quetiapine XR is superior to placebo in the reduction of anxiety symptoms in patients
with major depressive disorder and comorbid generalized anxiety disorder, the improvement of
the quality of sleep in patients with major depressive disorder and comorbid generalized
anxiety disorder and the improvement of the quality of life in patients with major depressive
disorder and comorbid generalized anxiety disorder.